From: Risk and outcome of pyelonephritis among renal transplant recipients
Characteristic | Pyelonephritis Hospitalization, No. | IRa (95 % CI) | Unadjusted IRR (95 % CI) | Adjustedb IRR (95 % CI) | P * Value |
---|---|---|---|---|---|
Recipient gender | |||||
Male | (122) | 13.0 (10.9–15.5) | 1 (Reference) | 1 (Reference) | |
Female | (139) | 29.3 (24.8–34.6) | 2.25(1.76–2.87) | 2.04(1.59–2.61) | <.001 |
Recipient, CCI-score | |||||
Low (0) | 131 | 15.9 (13.4–18.9) | 1 (Reference) | 1 (Reference) | |
Medium (1–2) | 60 | 17.8 (13.9–23.0) | 1.12 (0.83–1.52) | 0.98 (0.71–1.36) | .92 |
High (≥3) | 70 | 27.9 (22.0–35.2) | 1.75 (1.31–2.34) | 1.96 (1.16–3.31) | .01 |
Donor type | |||||
Cadaveric donor | 190 | 19.2 (16.6–22.1) | 1 (Reference) | 1 (Reference) | |
Living unrelated donor | 22 | 16.2 (10.7–24.6) | 0.85 (0.54–1.32) | 1.01 (0.65–1.58) | .95 |
Living related donor | 49 | 17.2 (13.0–22.8) | 0.90 (0.66–1.23) | 1.00 (0.71–1.39) | .98 |
HLA mismatch | |||||
AB mismatchc | |||||
<3 | 122 | 18.6 (15.5–22.2) | 1 (Reference) | 1 (Reference) | |
≥3 | 46 | 16.6 (12.4–22.2) | 0.90 (0.64–1.26) | 0.88 (0.62–1.25) | .49 |
DR mismatchc | |||||
<2 | 46 | 13.6 (10.2–18.1) | 1 (Reference) | 1 (Reference) | |
2 | 122 | 20.5 (17.2–24.5) | 1.51 (1.07–2.12) | 1.54 (1.10–2.18) | .01 |
Cause of ESRD | |||||
Glomerulonephritis | 46 | 10.3 (7.7–13.7) | 1 (Reference) | 1 (Reference) | |
Diabetes mellitus type 1 | 53 | 27.7 (21.2–36.2) | 2.69 (1.81–3.40) | 1.34 (0.73–2.48) | .35 |
Diabetes mellitus type 2 | 4 | 16.8 (6.33–44.9) | 1.64 (0.59–4.55) | 1.00 (0.33–2.99) | 1.00 |
Chronic interestitial nephritis | 44 | 31.7 (23.6–42.6) | 3.08 (2.04–4.66) | 2.53 (1.66–3.85) | <.001 |
Hypertensive kidney disease | 53 | 17.6 (13.4–23.0) | 1.71 (1.15–2.54) | 1.59 (1.06–2.37) | .02 |
Polycystic kidney disease | 39 | 19.2 (14.0–26.3) | 1.87 (1.22–2.86) | 1.66 (1.07–2.57) | .02 |
Vasculitis | 10 | 33.2 (17.9–61.7) | 3.23 (1.63–6.39) | 2.61 (1.28–5.30) | .01 |
Unkown | 12 | 15.9 (9.0–28.0) | 1.55 (0.82–2.92) | 1.18 (0.62–2.27) | .62 |
Posttransplant time | |||||
0–6 months | 83 | 69.9(56.4–86.7) | 1 (Reference) | 1 (Reference) | |
7–12 months | 29 | 26.9(18.7–38.7) | 0.38(0.25–0.59) | 0.39(0.25–0.59) | <.001 |
13–24 months | 33 | 16.9 (12.0–23.8) | 0.24 (0.16–0.36) | 0.24 (0.16–0.37) | <.001 |
+24 months | 116 | 11.7(9.8–14.0) | 0.17 (0.13–0.22) | 0.18 (0.13–0.24) | <.001 |
Recipient age | |||||
<50 years | 140 | 18.2 (15.4–21.5) | 1 (Reference) | 1 (Reference) | |
50–65 years | 98 | 18.7 (15.4–22.8) | 1.03 (0.79–1.33) | 1.06 (0.80–1.41) | .68 |
+65 years | 23 | 19.3 (12.8–29.1) | 1.06 (0.68–1.65) | 1.21 (0.76–1.93) | .43 |
Calendar period | |||||
1990–1994 | 35 | 29.8 (21.4–41.5) | 1 (Reference) | 1 (Reference) | |
1995–1999 | 67 | 22.5 (17.7–28.6) | 0.76 (0.50–1.14) | 0.73 (0.48–1.12) | .16 |
2000–2004 | 81 | 19.1 (15.4–23.7) | 0.64 (0.43–0.95) | 0.62 (0.41–0.94) | .02 |
2005–2009 | 78 | 13.6 (10.9–17.0) | 0.46 (0.31–0.68) | 0.42 (0.27–0.64) | <.001 |